Preserved GLP-1 effects in a diabetic patient with Cushing's disease

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 2, 2007, Pages 146-150

  Ritzel, R A ^a,b   Kleine, N ^c   Holst, J J ^d   Willms, B ^c   Schmiegel, W ^a   Nauck, M A ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; PLACEBO;

ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; HORMONE RELEASE; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROCORTISONE; INSULIN; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION;

EID: 33947100548     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-955096     Document Type: Article

References (23)

1. Achermann JC, Brook CG, Robinson IC, Matthews DR, Hindmarsh PC: Peak and trough growth hormone (GH) concentrations influence growth and serum insulin like growth factor-1 (IGF-1) concentrations in short children. Clin Endocrinol (Oxf) 1999; 50: 301-308
2. Atkinson AB, McCance DR, Kennedy L, Sheridan B: Cyclical Cushing's syndrome first diagnosed after pituitary surgery: a trap for the unwary. Clin Endocrinol (Oxf) 1992; 36: 297-299
3. Bierwolf C, Kern W, Molle M, Born J, Fehm HL: Rhythms of pituitary-adrenal activity during sleep in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 2000; 108: 470-479
4. Brubaker PL, Drucker DJ: Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology 2004; 145: 2653-2659 . Epub 2004 Mar 2624
5. Buteau J, Roduit R, Susini S, Prentki M: Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)- cells. Diabetologia 1999; 42: 856-864
6. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940
7. Giustina A, Veldhuis JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-797
8. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-1544
9. Holst JJ: Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982; 207: 381-388
10. Holst JJ: Glucagon-like peptide-1: from extract to agent, 2005. The Claude Bernard Lecture, 2005 Diabetologia 2006; 1-8
11. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304
12. Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997; 99: 414-423
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
14. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744
15. Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135-148
16. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M: A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43: 545-550
17. Orskov C, Holst JJ: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP- 1 and GLP-2). Scandinavian Journal of Clinical & Laboratory Investigation 1987; 47: 165-174
18. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall'omo AM, Imbimbo B: An in vivo and in vitro study of the mechanism of prednisoneinduced insulin resistance in healthy subjects. J Clin Invest 1983; 72: 1814-1820
19. Ritzel R, Orskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725
20. Taskinen MR, Nikkila EA, Pelkonen R, Sane T: Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 1983; 57: 619-626
21. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72
22. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002; 45: 1410-1415 . Epub 2002 Sep 1415
23. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332